Low intensity focused ultrasound: a new prospect for the treatment of Parkinson's disease

Ann Med. 2023;55(2):2251145. doi: 10.1080/07853890.2023.2251145.

Abstract

Background: As a chronic and progressive neurodegenerative disease, Parkinson's disease (PD) still lacks effective and safe targeted drug therapy. Low-intensity focused ultrasound (LIFU), a new method to stimulate the brain and open the blood-brain barrier (BBB), has been widely concerned by PD researchers due to its non-invasive characteristics.Methods: PubMed was searched for the past 10 years using the terms 'focused ultrasound', 'transcranial ultrasound', 'pulse ultrasound', and 'Parkinson's disease'. Relevant citations were selected from the authors' references. After excluding articles describing high-intensity focused ultrasound or non-Parkinson's disease applications, we found more than 100 full-text analyses for pooled analysis.Results: Current preclinical studies have shown that LIFU could improve PD motor symptoms by regulating microglia activation, increasing neurotrophic factors, reducing oxidative stress, and promoting nerve repair and regeneration, while LIFU combined with microbubbles (MBs) can promote drugs to cross the BBB, which may become a new direction of PD treatment. Therefore, finding an efficient drug carrier system is the top priority of applying LIFU with MBs to deliver drugs.Conclusions: This article aims to review neuro-modulatory effect of LIFU and the possible biophysical mechanism in the treatment of PD, summarize the latest progress in delivering vehicles with MBs, and discuss its advantages and limitations.

Keywords: Parkinson’s disease; low intensity pulsed ultrasound; low-intensity focused ultrasound; mechanism; microbubbles.

Plain language summary

Neuro-modulatory effects of LIFU at the cellular or molecular level.Opening the BBB through the combination of LIFU and MBs.Biophysical mechanism of LIFU.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Blood-Brain Barrier / physiopathology
  • Brain
  • Humans
  • Parkinson Disease* / therapy
  • Ultrasonography*

Grants and funding

This work was supported by the Natural Science Foundation of Guangdong Province (2018A0303130307), a grant from the Guangdong Basic and Applied Basic Research Foundation (2019A1515011739), and a grant from the Fundamental Research Funds for the Central Universities (19ykpy27).